{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:28:06Z","timestamp":1769502486465,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.diabres.2021.108916","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T01:19:58Z","timestamp":1623374398000},"page":"108916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin"],"prefix":"10.1016","volume":"182","author":[{"given":"Hideaki","family":"Jinnouchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Tsuyuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoko","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunio","family":"Hieshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Kurinami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomio","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2021.108916_b0005","doi-asserted-by":"crossref","unstructured":"Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271-281. PMID:29496507. doi: 10.1016\/j.diabres.2018.02.023.","DOI":"10.1016\/j.diabres.2018.02.023"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2021.108916_b0010","first-page":"S1","article-title":"Introduction: Standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108916_b0015","unstructured":"Japan Diabetes Clinical Data Management Study Group. Basic accumulated data 2018. http:\/\/jddm.jp\/data\/index-2018\/. Accessed January 27, 2020. (in Japanese)"},{"key":"10.1016\/j.diabres.2021.108916_b0020","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108916_b0025","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabres.2021.108916_b0030","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.108916_b0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: A meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.diabres.2021.108916_b0040","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/03007995.2014.912983","article-title":"Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, phase 3 study","volume":"30","author":"Seino","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2021.108916_b0045","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.diabres.2021.108916_b0050","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1210\/endo.141.11.7757","article-title":"Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans","volume":"141","author":"Date","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabres.2021.108916_b0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/gast.2001.22158","article-title":"Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin","volume":"120","author":"Asakawa","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2021.108916_b0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35051587","article-title":"A role for ghrelin in the central regulation of feeding","volume":"409","author":"Nakazato","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.diabres.2021.108916_b0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1006\/bbrc.2000.4039","article-title":"Ghrelin and desacyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue","volume":"279","author":"Hosoda","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.diabres.2021.108916_b0070","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1083\/jcb.200207165","article-title":"Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1\/2 and PI 3-kinase\/AKT","volume":"159","author":"Baldanzi","year":"2002","journal-title":"J Cell Biol"},{"key":"10.1016\/j.diabres.2021.108916_b0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0014-2999(03)02083-1","article-title":"Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin","volume":"476","author":"Bedendi","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.diabres.2021.108916_b0080","first-page":"1738","article-title":"Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines","volume":"86","author":"Cassoni","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2021.108916_b0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/gut.2004.038737","article-title":"Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin","volume":"54","author":"Asakawa","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.diabres.2021.108916_b0090","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s13300-019-0666-7","article-title":"Concurrent use of teneligliptin and canagliflozin improves glycemic control with beneficial effects on plasma glucagon and glucagon-like peptide-1: A single-arm study","volume":"10","author":"Noda","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2021.108916_b0095","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/jdi.13015","article-title":"Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study)","volume":"10","author":"Miura","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2021.108916_b0100","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.diabres.2003.11.024","article-title":"Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes","volume":"66","author":"Fukushima","year":"2004","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2021.108916_b0105","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108916_b0110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdi.12851","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study","volume":"10","author":"Sasaki","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2021.108916_b0115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diabres.2018.05.017","article-title":"Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus","volume":"142","author":"Kurinami","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2021.108916_b0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.diabres.2021.108916_b0125","first-page":"121","article-title":"Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization","volume":"7","author":"Xu","year":"2018","journal-title":"Adipocyte"},{"key":"10.1016\/j.diabres.2021.108916_b0130","doi-asserted-by":"crossref","unstructured":"Seino Y, Inagaki N, Heneda M, et al. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2015 Jul; 6(4): 443-453.30.","DOI":"10.1111\/jdi.12316"},{"key":"10.1016\/j.diabres.2021.108916_b0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12944-017-0443-4","article-title":"A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes","volume":"16","author":"Cha","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.diabres.2021.108916_b0140","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/dia.2019.0099","article-title":"Efficacy and safety of tofogliflozin on 24-h glucose profile based on continuous glucose monitoring: Crossover study of sodium-glucose cotransporter 2 inhibitor","volume":"21","author":"Kurozumi","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabres.2021.108916_b0145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/dia.2018.0052","article-title":"Effects of dapagliflozin on 24-hour glycemic control in patients with type 2 diabetes: A randomized controlled trial","volume":"20","author":"Henry","year":"2018","journal-title":"Diabetes Technol Ther"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272100276X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272100276X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:20:00Z","timestamp":1759173600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882272100276X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":29,"alternative-id":["S016882272100276X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108916","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108916"}}